Oral GLP-1 Receptor Agonist Orforglipron Beneficial for Adults With Obesity, T2DM
WEDNESDAY, Dec. 3, 2025 — The oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist orforglipron demonstrates superior weight loss as an adjunct to lifestyle modification versus placebo for adults with obesity or overweight and type…
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and expand their market positions amid soaring demand. Lilly announced meaningful price cuts to its tirzepatide-based obesity drug Zepbound, reducing out-of-pocket costs on […]
States retreat from covering drugs for weight loss
Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for the cuts included in President Donald Trump’s broad tax and spending law.
Could SGLT2 Inhibitors Reduce Rheumatoid Arthritis Flares?
Two ACR 2025 analyses link SGLT2 inhibitors to fewer RA flares and a lower risk for osteoarthritis than GLP-1 receptor agonists, though randomized trials are still needed. Medscape News Europe
Open Enrollment Snapshot: 77% of Americans Are Pleased with Their Health Insurance Options for 2026
Regarding GLP-1 drugs, 33% of Americans intend to begin taking these medications for weight loss once the Trump administration makes them available at discounted prices next year 57% of Americans say the Trump administration is making the needs of health insurance enrollees a high…
WHO issues a global guideline on the use of GLP-1 medicines in treating obesity
WHO issues conditional recommendations for using these therapies to support people living with obesity in overcoming this serious health challenge, as part of a comprehensive approach that includes healthy diets, regular physical activity and support from health professionals
WHO issues guidance on GLP-1 drugs for obesity, calls them a “scientific breakthrough” and “new chapter” – CBS News
WHO issues guidance on GLP-1 drugs for obesity, calls them a “scientific breakthrough” and “new chapter” CBS News WHO issues global guideline on the use of GLP-1 medicines in treating obesity World Health Organization (WHO) World Health Organization issues first-ever guidelines for use of GLP-1 weight loss medications ABC News WHO warning over shortage of obesity jabs BBC WHO […]
User Engagement in a Weight-Loss App Boosts GLP-1 Success
User engagement in a digital weight-loss program yielded better results in participants taking GLP-1 receptor agonists than nonengagement in the app. Medscape Medical News
Nutrients, Vol. 17, Pages 3789: The Effect of a Low-Energy and Low-Glycemic Diet on Adipose Tissue Metabolism and Energy Expenditure in Women with Excess Body Weight
Nutrients, Vol. 17, Pages 3789: The Effect of a Low-Energy and Low-Glycemic Diet on Adipose Tissue Metabolism and Energy Expenditure in Women with Excess Body Weight Nutrients doi: 10.3390/nu17233789 Authors: Ewa Lange Ewelina Pałkowska-Goździk Background/Objectives: Data indicate that a low-glycemic index diet may be an effective nutritional approach to improve cardiometabolic parameters and support weight […]
GLP-1 drugs alone aren’t a magic fix — My patient’s story shows what really works
Post Content